We evaluated the ability of different trypsin-revealed tethered ligand (TL) sequences of rat proteinase-activated receptor 2 (rPAR 2 ) and the corresponding soluble TL-derived agonist peptides to trigger agonist-biased signaling. To do so, we mutated the proteolytically revealed TL sequence of rPAR 2 and examined the impact on stimulating intracellular calcium transients and mitogen-activated protein (MAP) Ser 38 constructs recruited ␤-arrestins-1 or -2 in response to trypsin stimulation, whereas both ␤-arrestins were recruited to these mutants by SLIGRL-NH 2 . The lack of trypsin-triggered ␤-arrestin interactions correlated with impaired trypsin-activated TL-mutant receptor internalization. Trypsinstimulated MAP kinase activation by the TL-mutated receptors was not blocked by inhibitors of G␣ i (pertussis toxin),
, rPAR 2 -Ala [37] [38] , and rPAR 2 -Ala 39-42 were compared with the trypsin-revealed wild-type rPAR 2 TL sequence, S 37 LIGRL 42 -. Upon trypsin activation, all constructs stimulated MAP kinase signaling, but only the wt-rPAR 2 and rPAR 2 -Ala 39-42 triggered calcium signaling. Furthermore, the TL-derived synthetic peptide SLAAAA-NH 2 failed to cause PAR 2 -mediated calcium signaling but did activate MAP kinase, whereas SLIGRL-NH 2 triggered both calcium and MAP kinase signaling by all receptors. The peptides AAIGRL-NH 2 and LSIGRL-NH 2 triggered neither calcium nor MAP kinase signals. Neither rPAR 2 -Ala 37-38 nor rPAR 2 -Leu 37 Ser 38 constructs recruited ␤-arrestins-1 or -2 in response to trypsin stimulation, whereas both ␤-arrestins were recruited to these mutants by SLIGRL-NH 2 . The lack of trypsin-triggered ␤-arrestin interactions correlated with impaired trypsin-activated TL-mutant receptor internalization. Trypsinstimulated MAP kinase activation by the TL-mutated receptors was not blocked by inhibitors of G␣ i (pertussis toxin), G␣ q [Ncyclohexyl-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno-[1,2-c]pyrazole-3-carboxamide (GP2A)], Src kinase [4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1)], or the epidermal growth factor (EGF) receptor [4-(3Ј-chloroanilino)-6,7-dimethoxy-quinazoline (AG1478)], but was inhibited by the Rhokinase inhibitor (R)-(ϩ)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 2HCl (Y27362). The data indicate that the proteolytically revealed TL sequence(s) and the mode of its presentation to the receptor (tethered versus soluble) can confer biased signaling by PAR 2 , its arrestin recruitment, and its internalization. Thus, PAR 2 can signal to multiple pathways that are differentially triggered by distinct proteinase-revealed TLs or by synthetic signal-selective activating peptides.
Proteinase-activated receptors (PARs) are unique members of the G-protein-coupled superfamily of receptors (GPCRs), modeled as seven transmembrane domain cell-surface receptors that mediate diverse signaling events in response to proteolytic exposure of an N-terminal tethered ligand (TL) sequence. PAR 2 , the second member of this family to be cloned (Nystedt et al., 1994; Bohm et al., 1996) Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org. doi:10.1124/mol.109.055509.
serine proteinase-activated class A GPCR with an unusual TL receptor activation mechanism (Coughlin, 2000; Ramachandran and Hollenberg, 2008) . Proteolytic cleavage by serine proteinases, prototypically trypsin for PAR 2 , reveals a sequence within the receptor N terminus (Ser   37   LIGRLDTP   45 -in rodent PAR 2 ), that then acts as a TL, presumably by interacting with other cell surface receptor domains. It is noteworthy that PAR 2 is also triggered by soluble synthetic receptor-activating peptides with sequences corresponding to that of the proteolytically revealed TL (e.g., SLIGRL-NH 2 ).
Our previous work, aimed at identifying PAR 2 TL amino acids responsible for signaling, has delineated residues within the trypsin-revealed receptor TL sequence that are critical for triggering elevations in intracellular calcium (Al-Ani et al., 2004) . The first two amino acids of the trypsin-revealed TL (Ser 37 Leu 38 ) were found to be important, such that a revealed rat PAR 2 mutated TL sequence, SLAAAA-, was able to stimulate increases in intracellular calcium, whereas the revealed mutated TL sequences LSIGRL-and AAIGRL-were not. Furthermore, we showed that, whereas the sequence SLAAAA-could activate calcium signaling as a tethered ligand, the corresponding soluble synthetic peptide, SLAAAA-NH 2 , was unable to do so. These data pointed to differences in signal trafficking by PAR 2 depending on whether it is activated by its own proteolytically revealed TL or by an analogous synthetic peptide. For many other GPCRs, such as those for angiotensin II, dopamine, serotonin, and adrenergic ligands, it is now accepted that there can be differential signaling, depending on the activating ligand. This agonist-dependent differential signaling has been termed "agonist-biased signaling" or "functional selectivity" (Wei et al., 2003; Galandrin et al., 2007; Kenakin, 2007; Urban et al., 2007) . We therefore hypothesized that, in a unique way, the trypsin-revealed PAR 2 TL might, depending on its sequence, exhibit functional selectivity, so as to target signaling to distinct responses (e.g., calcium versus MAP kinase). To test this hypothesis, we examined rat PAR 2 receptor mutants with different revealed TL sequences (described above) for their ability to signal (or not) by 1) either elevating intracellular calcium or activating ERK/p42/44 MAP kinase (or both), 2) recruiting ␤-arrestins-1 and -2, and 3) promoting endocytosis. These three responses were monitored upon activating the wild-type and TL-mutated receptors both by a proteinase (trypsin) and by a series of soluble synthetic PAR-AP analogs with amino acid sequences corresponding to those of the N-terminal proteinase-revealed wild-type or mutated tethered ligands.
Materials and Methods
Chemicals and Other Reagents. Enzyme inhibitors (PP1 for Src; Y27362 and H1152 for Rho kinase; doxycycline for metalloproteinases; PD153035/AG1478 for the EGF receptor kinase) were obtained from Calbiochem (La Jolla, CA). The G␣ q inhibitor GP2A (used at a concentration of 10 M) was from Tocris Bioscience (Ellisville, MO). Culture medium (Dulbecco's modified Eagle's medium) and fetal bovine serum were from Invitrogen Life Sciences (Burlington, ON, Canada). Pertussis toxin and calcium ionophore A23187 were from Sigma (St. Louis, MO). Porcine trypsin (approximately 14,900 units/mg) was also obtained from Sigma (St. Louis, MO). A maximum specific activity of 20,000 units/mg was used to calculate the approximate molar concentration of trypsin in the incubation medium (1 unit/ml Х 2 nM). All PAR-activating peptides and analogs were synthesized as C-terminally amidated products by the Faculty of Medicine Peptide Synthesis facility at the University of Calgary with purity verified by amino acid analysis and mass spectral analysis.
Expression Vectors. The plasmid encoding the rat PAR 2 receptor (wt-rPAR 2 ) and the tethered ligand mutated rat PAR 2 receptor variants LSIGRL (rPAR 2 -Leu 37 Ser 38 ) or AAIGRL (rPAR 2 -Ala 37-38 ) (Table 1) were constructed as described previously (Al-Ani et al., 2004) . The YFP-tagged variants for all the constructs were generated by ligating the PAR genes into the pEYFP-N1 vector (Clontech, Mountain View, CA). Plasmids encoding the G␣ 12 and G␣ 13 genes in the pCDNA3.1ϩ vector were obtained from the University of Missouri S&T cDNA Resource Center (Rolla, MO). The sequences for all constructs were confirmed by sequencing.
Cell Lines and Transfection. KNRK or HEK-293 cells were routinely cultured as outlined previously and passaged without the use of trypsin using an isotonic EDTA-containing dissociation buffer Al-Ani et al., 2004 ) in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% sodium pyruvate, and 1% antibiotic antimycotic solution. The KNRK cells do not express functional PAR 2 , as do the HEK-293 cells, and were thus used to generate the permanent PAR 2 -expressing cell lines (Table 1) for an evaluation of calcium signaling and MAP kinase activation, in keeping with previous work (Al-Ani et al., 2004) . The studies of transiently transfected cells [bioluminescence resonance energy transfer (BRET) and internalization] were done with the HEK-293 cells because of their greater transfection efficiency compared with the KNRK cells. Mouse embryonic fibroblasts, wild type (MEF WT) and ␤-arrestin double knockout (MEF DKO), were a gift generously provided by Dr. Robert Lefkowitz (Duke University, Durham, NC) and were routinely cultured as above, except that cells were passaged by trypsin dissociation followed by repeated feeding with trypsin-free growth medium. Transfections were performed on cells that were approximately 80% confluent with Lipofectamine (Invitrogen) or FuGENE6 (Roche, Laval, QC, Canada). MEF cells were transfected by the calcium phosphate method as described previously (Chen and Okayama, 1987) . KNRK cells stably expressing equivalent levels of wild-type or the TL-mutant rPAR 2 were selected by quantifying cell surface receptor expression levels with flow cytometry using the B5 PAR 2 selective antibody as described previously (Al-Ani et al., 2004) . To test G␣ 12 and G␣ 13 involvement in rPAR 2 signaling, KNRK cells stably expressing wt-rPAR 2 , rPAR 2 -Leu 37 Ser 38 , or rPAR 2 -Ala 37-38 were transiently transfected with plasmids encoding the G␣ 12 and the G␣ 13 genes for 48 h before use in experiments studying cell signaling.
Calcium Signaling. Calcium signaling responses were monitored as described previously . In brief, cells were grown to 80% confluence, lifted in enzyme-free cell dissociation buffer (Invitrogen), and incubated with 5 M Fluo3-acetoxymethyl ester (Invitrogen) for 30 min at room temperature in the presence of sulfinpyrazone (0.25 mM). Fluo3-loaded cells, washed free of extracellular calcium indicator, were placed in stirred plastic cuvettes (VWR, West Chester, PA) and agonist-stimulated calcium mobilization and concomitant increases in fluorescence were monitored with an Aminco Bowan series II fluorimeter using the AB2 software (Thermo Fisher Scientific, Nepean, ON, Canada). Calcium signals monitored using an excitation wavelength of 480 nm and an emission wavelength recorded at 530 nm were expressed as a percentage of the emission fluorescence caused by 2 M calcium ionophore A23187 . Total-ERK immunoreactivity was detected using the secondary horseradish peroxidase conjugated anti-rabbit antibody (1/15,000 in TBST/5% milk for 1 h), and the peroxidase activity was detected using a chemiluminescence reagent (ECL-plus; GE Healthcare) with X-ray film detection (Kodak) or using a chemiluminescent gel doc system (Bio-Rad Laboratories, Mississauga, ON, Canada). Images were digitized and band intensities were quantified using the ImageJ quantification software (http://rsbweb.nih.gov/ij/). Phospho-ERK1/2/phospho-p42/44 MAP kinase levels were normalized for differences in protein loading by expressing the data as a percentage of the corresponding total ERK1/2/p42/44 MAP kinase signal (pERK/tERK; Pp43/44 MAP kinase/Tp43/44 MAP kinase) detected with a pan-MAP kinase/ERK antibody. In-Cell Western Analysis. For all in-cell western analysis, calcium phosphate-transfected WT or DKO MEF cells were seeded into clear-bottomed black 96-well tissue culture-treated plates (Nalge Nunc International, Rochester, NY), grown to confluence and serumstarved overnight, treated with 10 nM trypsin for 0 to 90 min at 37°C, and then fixed in normal buffered formalin. Cells were gently permeabilized with phosphate-buffered isotonic saline, pH 7.4 (PBS) supplemented with 0.1% Triton X-100, then blocked for 1 h with PBS ϩ 1% fish gelatin (Sigma). Plates were incubated overnight at 4°C with primary antibody solutions (pERK, 1:500; Cell Signaling Technology, Danvers, MA) and (tERK, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA) in PBS containing 1% (w/v) fish gelatin. Plates were washed three times with PBS, supplemented with 0.5% Tween 20, and then incubated with IR680 and IR800-conjugated secondary antibodies (1:2000; LI-COR Biosciences, Lincoln, NE) diluted in PBS/1% (w/v) fish gelatin for 1 h at room temperature. Plates were washed three times in PBS-Tween 20 and once in PBS only and then analyzed using the Odyssey infrared imaging system (LI-COR). Odyssey software was used to calculate integrated intensities of each well for quantification. A -fold increase in ERK1/2 phosphorylation (normalized to total ERK levels) over baseline was calculated.
BRET-Based Detection of ␤-Arrestin Interaction with wtrPAR 2 and TL-Mutated Receptors. The wild-type and mutated receptors (wt-rPAR 2 , rPAR 2 -Leu 37 Ser 38 , and rPAR 2 -Ala 37-38 constructs) were conjugated with YFP at the C terminus (rPAR 2 -YFP, rPAR 2 Leu 37 Ser 38 -YFP, and rPAR 2 Ala 37-38 -YFP) and BRET to Renilla reniformis luciferase-tagged ␤-arrestin-1 and -2 was determined essentially as described previously (Hamdan et al., 2007) . HEK-293 cells were used instead of the KNRK cell line, because the HEK cells provide for a much greater transfection efficiency, which is required for the BRET studies. In brief, HEK-293 cells were transiently transfected with 1 g of either rPAR 2 -YFP, rPAR 2 Leu 37 Ser 38 -YFP, or rPAR 2 Ala 37-38 -YFP along with 0.1 g of the R. reniformis luciferase-tagged ␤-arrestin-1 and -2. Cells were plated in white 96-well culture plates (PerkinElmer Life and Analytical Sciences, Waltham, MA) and interactions between the receptors and ␤-arrestin were detected by BRET following the addition of 5 M coelenterazine (Promega, Madison, WI) on a Mithras fluorescence plate reader (Berthold Technologies, Bad Wildbad, Germany) in luminescence mode using the appropriate filters. The kinetics of ␤-arrestin recruitment to the receptors was monitored over 20 min.
Microscopy. HEK cells were plated on glass-bottomed Petri dishes (MatTek Corp., Ashland, MA) and transiently transfected with 1 g of rPAR 2 -YFP, rPAR 2 -Leu 37 Ser 38 -YFP, or rPAR 2 -Ala 37-38 -YFP constructs. After 48 h, the media in the Petri dish was replaced with serum-free medium, and the cells were treated with Trypsin (10 nM) or SLIGRL-NH 2 (10 M) for 30 min at 37°C. After fixation of cells with 4% formaldehyde, the cellular localization of the receptor tag YFP signal was detected using an Olympus FV1000 confocal system on an Olympus IX70 microscope with the Fluoview system software (Olympus, Tokyo, Japan). Internalization of cell surface receptor was quantified morphometrically by counting the increased number of intracellular fluorescent speckles per cell in the images, indicative of receptor internalization to endocytic vesicles. To this end, speckles in all cells were counted in a randomly selected representative 40ϫ image, with area dimensions approximately 100 ϫ 100 m (Fig. 9) . The average number of speckles per cell was calculated, and the observation was repeated for comparable fields for cells observed in three independently conducted experiments. Data represent the averages of speckles per cell Ϯ S.E.M. for three or more independent experiments.
Statistical Analysis. Statistical analysis of data and curve fitting were done with Instat and Prism 5 software (GraphPad Software, San Diego, CA). Statistical significance was assessed using the Student's t test. In the histograms representing the Western blot data, averages are shown Ϯ S.E.M. for three or more independent measurements of band density.
Results
Calcium Signaling. In keeping with our previous work , we observed that activation of wtrPAR 2 by either trypsin or the receptor-selective PAR 2 -activating peptide SLIGRL-NH 2 stimulates an increase in intracellular calcium in a concentration-dependent manner, with an EC 50 for trypsin of approximately 1 nM (Fig. 1A ) and an EC 50 for SLIGRL-NH 2 of approximately 5 M (not shown; Al-Ani et al., 2004) . Reversal of the first two amino acids of the rPAR 2 tethered ligand sequence to generate the construct rPAR 2 -Leu 37 Ser 38 resulted in a receptor that was unable to recruit calcium signaling after activation by trypsin but still remained responsive in terms of calcium signaling upon stimulation by SLIGRL-NH 2 (Fig. 1B) . Alanine substitution of the first two amino acids in the TL sequence of rPAR 2 generated the construct rPAR 2 Ala [37] [38] , which, like the rPAR 2 Leu 37 Ser 38 construct, failed to trigger an elevation of intracellular calcium when cleaved by trypsin (Fig. 1A) but did yield an intracellular calcium signal in response to SLIGRL-NH 2 activation (Fig. 1B) . The EC 50 for SLIGRL-NH 2 -stimulated calcium signaling by the TL-mutant receptors (EC 50 ϳ 5 M: data not shown) was equivalent to that for the wild-type receptor, illustrating that the mutations did not affect the ability of the receptor to respond to activating stimuli but rather that the modified trypsin-revealed , although unable to trigger calcium signaling in response to trypsin, might activate MAP kinase, we incubated KNRK cells expressing these constructs with 10 nM trypsin. We observed that trypsin stimulated a rapid increase in phospho-p42/44 levels (maximal at 5 to 10 min after trypsin exposure; see Figs. 2 and 3) that was not observed in the empty vector-transfected KNRK cells (Fig. 2) . The maximal MAP kinase response seen in cells expressing the TL-mutated PAR 2 constructs was approximately 70% of the response of the wt-rPAR 2 transfected cells. Because the persistence of the MAP kinase signal is thought to be important for a number of physiological responses, we investigated the time course of MAP kinase activation in cells transfected with wild-type and TL-mutated PAR 2 constructs (Fig. 3) . We observed that in all cell lines, 10 nM trypsin stimulated a robust increase in MAP kinase that was maximal after approximately 5 min, persisted for 40 min, and began to decline thereafter, but remained above baseline for at least 1 h.
Inhibition of G q and G i Modestly Attenuates MAP Kinase Activation by Trypsin in wt PAR 2 but Not in the TL-Mutant Cell Lines. Because PAR 2 -dependent calcium signaling is reported to be G q -coupled, we evaluated ; Ⅺ, pcDNA3) were exposed to trypsin at increasing concentrations and the elevation of intracellular calcium relative to the signal caused by 1 M A23187 (% A23187) was monitored as described under Materials and Methods. Trypsin concentration-effect curve for calcium signaling (A) and calcium signaling (% A23187) (B) triggered by SLIGRL-NH 2 (300 M) in wt-rPAR 2 (f), rPAR 2 -Leu whether the MAP kinase signaling observed in response to activation of the wt-rPAR 2 as well as the tethered ligand mutants rPAR 2 -Leu 37 Ser 38 and rPAR 2 -Ala 37-38 by trypsin was dependent on G q coupling. To suppress G q signaling, cell lines were treated with the G␣ q inhibitor GP2A (10 M) (Zoudilova et al., 2007) before activation with the same concentration of trypsin that stimulated MAP kinase activation. As a control, the ability of GP2A to block trypsin-triggered calcium signaling in the wt-rPAR 2 KNRK cell line was tested. Because neither of the mutated TL PAR 2 cell lines signal via calcium when activated by trypsin, they were not tested in this way. Efficient (Ͼ90%) inhibition of G q -mediated calcium signaling was observed in terms of the complete suppression of trypsin-triggered effects by 10 M GP2A in the wt-rPAR 2 cell line (not shown). However, in the wt-PAR 2 cell line, the G q inhibitor caused only a modest inhibition (approximately 30%) of trypsin-triggered MAP kinase activation (Fig. 4b) . In contrast, under the same conditions in the presence of the G q inhibitor GP2A, we observed no difference in the ability of trypsin to activate the p42/44 MAP kinase pathway in the two cell lines with mutated TL sequence (rPAR 2 Leu 37 Ser 38 and rPAR 2 Ala 37-38 ; Figs. 5 and 6). This lack of inhibition of MAP kinase activation was in contrast with the ability of GP2A to block SLIGRL-NH 2 -mediated calcium signaling in the rPAR 2 Leu 37 Ser 38 and rPAR 2 Ala 37-38 -expressing cells (not shown). Thus, although upon PAR-AP activation the mutant receptors can engage G q to promote calcium mobilization, the activation of G q was not involved in the ability of these receptors to activate ERK1/2 when stimulated by trypsin. Furthermore, treatment of cells with pertussis toxin (PTX; 100 ng/ml; 16 h) to compromise G i coupling had no effect on the ability of trypsin or SLIGRL-NH 2 to cause calcium signaling in all three cell lines (not shown). In the TL-mutant cell lines, PTX treatment was similarly ineffective in blocking trypsin-activated MAP kinase signaling, although in the wt-PAR 2 cell line, PTX caused a small (approximately 30%) inhibition of trypsin-triggered MAP kinase activation (Figs. 4-6) . Thus, we concluded that in the TLmutant cell lines, trypsin-mediated MAP kinase activation was independent of both G i and G q coupling, whereas in the wt-PAR 2 cell line, MAP kinase activation by trypsin was partially G q -and G i -dependent. 4 . Effects of inhibitors on trypsin-stimulated MAP kinase signaling in wt-rPAR 2 KNRK cells. KNRK cells expressing wt-rPAR 2 were activated by trypsin (10 nM, 10 min.) in the absence or presence of the indicated inhibitors, followed by Western blot analysis of MAP kinase activation (P-p42/44), relative to total enzyme (T-p42/44). A, representative Western blots visualizing activated (top gel, P-p42/4) and total enzyme (bottom gel, T-p42/44). B, quantitative densitometric image analysis for the percentage increase over baseline of P-p42/44 normalized to T-p42/44, integrating the signal for both bands visualized for P-p42/44 relative to T-p42/44. Asterisks denote a significant increase ‫,ء(‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001) compared with unstimulated cells (NT). Pound signs denote a significant decrease (#, P Ͻ 0.15; ##, P Ͻ 0.01) between the stimulation by trypsin in the presence of the Rho-kinase inhibitor Y27362 compared with cells stimulated by trypsin in the absence of the inhibitor. Data are representative of three independent experiments.
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at ASPET Journals on July 8, 2017 molpharm.aspetjournals.org Downloaded from PAR 2 Mediated Activation of MAP Kinase Does Not Involve Transactivation of the EGFR. In view of the ability of PAR 2 , like other G-protein-coupled receptors, to cause signaling by transactivation of the EGF receptor (EGFR) (Daub et al., 1996; McCole et al., 2002; Darmoul et al., 2004; van der Merwe et al., 2008) , we tested the hypothesis that EGFR transactivation triggered by the metalloproteinase-catalyzed release of an EGFR ligand (heparin-binding EGF or transforming growth factor-␣) might be involved in trypsin-mediated activation of either calcium signaling or MAP kinase in the wild-type or mutant TL-PAR 2 cell lines. In KNRK cells transfected with wt-rPAR 2 , neither the EGFR kinase inhibitor AG1478 (1 M) nor the broad-spectrum matrix metalloproteinase (MMP) inhibitor doxycycline (0.1 mM) inhibited calcium signaling activated by trypsin (not shown). Furthermore, neither AG1478 nor doxycycline had any effect on MAP kinase activation in any of the cell lines tested (Figs.  4-6) . These results argued strongly against a role for transactivation of the EGFR in the activation of MAP kinase by trypsin in the PAR 2 -expressing KNRK cell lines.
Involvement of Src and Rho-Kinase in Trypsin-Mediated Activation of MAP Kinase. To assess the potential role of Src and Rho kinase in mediating PAR 2 signaling, we tested the ability of the Src-selective inhibitor PP1 (Hanke et al., 1996) and the Rho kinase inhibitor Y27362 (10 M) (Uehata et al., 1997) to attenuate trypsin-mediated MAP kinase activation. As shown in Figs. 4 to 6, the Src-kinase inhibitor inhibited MAP kinase activation by approximately 30% in the wt-rPAR 2 cell line (Fig. 4) but had no effect on trypsin-mediated MAP kinase activation in the TL mutant cell lines (Figs. 5 and 6 ). In contrast, the Rho kinase inhibitor blocked trypsin-triggered activation by more than 80% in all cell lines. Similar results were observed with the more potent Rho-kinase inhibitor H1152 (1 M, not shown). To determine whether the Rho kinase-dependent signal observed was downstream of G␣ 12/13 , we overexpressed constructs encoding G␣ 12 and G␣ 13 into KNRK cells stably expressing rPAR 2 -Leu 37 Ser 38 . We note an increased sensitivity to trypsin activation of MAPK in these cells with a signal observed with exposure to 5 nM trypsin, which is absent in control cells not overexpressing G␣ 12 and G␣ 13 (Fig. 7) . Similar results were observed with the rPAR 2 -Ala 37-38 receptor (not shown). ␤-Arrestin Interactions and PAR 2 -Mediated MAP Kinase Signaling. Previous work has pointed to a role for ␤-arrestin in facilitating a prolonged activation of MAP kinase by PAR 2 (Ge et al., 2003) , and it has been proposed that PAR 2 may trigger responses distinct from a G q -coupled elevation of intracellular calcium by a ␤-arrestin-mediated pathway (Zoudilova et al., 2007) . We therefore tested the potential role(s) of ␤-arrestins in trypsin-mediated MAP kinase activation in the different PAR 2 cell lines. To evaluate the role(s) of ␤-arrestins, we assessed MAP kinase signaling triggered by trypsin in DKO MEFs transfected with the wt-rPAR 2 -YFP and the TL mutated constructs rPAR 2 -Leu 37 Ser 38 -YFP and rPAR 2 -Ala 37-38 -YFP. When expressed in the DKO MEF background, all receptor constructs showed an increase in MAP kinase activation in response to trypsin as was observed in the KNRK cells. MAP kinase activation was greater for wt-rPAR 2 (approximately 6-fold over baseline) than for both of the TL-mutated constructs (2-4-fold over baseline) (Fig. 8, A-C, top) . However, in the DKO MEF cells expressing wt-rPAR 2 , a reduction in the magnitude of the trypsin-activated MAP kinase signal was observed (ϳ2-fold over baseline), whereas MAP kinase activation by the TL-mutated receptors was similar to that observed in wtMEFs (ϳ2-fold for rPAR 2 -Ala 37-38 -YFP and ϳ3-fold for rPAR 2 -Leu 37 Ser 38 -YFP) (Fig. 8, B and C). Thus, the MAP kinase activation by wt-rPAR 2 seemed to be partially ␤-arrestin-dependent, whereas the magnitude of MAP kinase activation caused by trypsin activation of the PAR 2 -Ala -YFP Do Not. The above result suggested that in contrast to the wt-rPAR 2 , the trypsin-activated mutant forms of the receptor might not recruit ␤-arrestin. To test this possibility, we used a BRET approach to monitor the interactions of ␤-arrestin-1 and -2 with wt-rPAR 2 , rPAR 2 -Leu 37 Ser 38 -YFP, or rPAR 2 -Ala 37-38 -YFP upon activation of the receptors either by trypsin or by the PAR 2 -activating peptide, SLIGRL-NH 2 . We observed that when stimulated with trypsin ( Fig. 9 and Supplementary Information), only the wild-type rPAR 2 showed a time-dependent increase in BRET, indicating interactions with both ␤-arrestin 1 (Supplementary Information) and ␤-arrestin 2 (Fig. 9A) . The BRET signals for the interaction of wild-type rPAR 2 with both ␤-arrestins-1 and -2 were comparable, whether activated by trypsin or the PARactivating peptide SLIGRL-NH 2 ( -YFP with trypsin failed to generate a BRET signal with either of ␤-arrestin-1 or -2 (Fig. 9 , C and D, and data not shown for ␤-arrestin-1; see Supplementary Information). Notwithstanding, activation of the TL-mutant receptors with the PAR 2 -activating peptide SLIGRL-NH 2 was able to generate a BRET signal for the recruitment of either ␤-arrestin-1 (not shown and see Supplementary Information) or ␤-arrestin-2 (Fig. 9, C and D, insets) , respectively. Thus, although the two TL mutant receptors were in principle able to interact with both ␤-arrestin-1 and -2 (activation by SLI-GRL-NH 2 ), the trypsin-exposed mutant TL sequences failed to promote a receptor-␤-arrestin interaction, as reflected by the BRET measurements.
Impaired Internalization of TL-Mutated PAR 2 Receptors after Trypsin Activation. ␤-Arrestin interaction is known to be critical for internalization of PAR 2 (Ge et al., 2003) . Because we observed impaired ␤-arrestin interaction with the TL-modified PAR 2 constructs, we wished to investigate the internalization of wt-rPAR 2 , rPAR 2 -Leu -YFP transiently transfected in HEK cells were treated with agonists for 30 min, and receptor internalization was quantified by morphometric analysis as described under Materials and Methods. We observed that the wt-rPAR 2 receptor showed significant internalization after both trypsin (10 nM) and SLIGRL-NH 2 (10 M) activation, with the magnitude of trypsin-triggered internalization approaching that of internalization triggered by the synthetic activating peptide (Fig. 10,  A, ii and iii, and B) . In contrast, trypsin-mediated internalization of the TL-mutant receptors was markedly diminished, relative to that of the wild-type receptor (Fig. 10, A, v 
Agonist-Biased Signaling via PAR 2 797
at ASPET Journals on July 8, 2017 molpharm.aspetjournals.org was equivalent to peptide-triggered internalization of the wildtype receptor.
SLAAAA-NH 2 as a Biased Agonist for PAR 2 . We observed that the trypsin-revealed N-terminal sequence of the PAR 2 mutant PAR 2 -Ala 39-42 (exposed TL sequence: SLAAAA-) could signal to both calcium (data not shown; Al-Ani et al., 2004) and MAP kinase (Supplementary Information) but that the corresponding TL-derived synthetic soluble peptide SLAAAA-NH 2 could not cause PAR 2 -mediated calcium signaling (data not shown; Al-Ani et al., 2004) . We thus wondered whether this peptide might be able to cause biased signaling by PAR 2 so as to activate MAP kinase. Although it could not cause an elevation of intracellular calcium, this peptide was able to stimulate MAP kinase activation in both the wild-type and mutated receptor constructs (Fig. 11) . In contrast, the peptides AAIGRL-NH 2 and LSIGRL-NH 2 , corresponding to the revealed TL sequences in PAR 2 -Ala 37-38 and PAR 2 -Leu 37 Ser 38 , were not able to activate either calcium (not shown) or MAP kinase signaling (Fig. 10, top) .
Discussion
The main finding of our study was that distinct trypsinrevealed PAR 2 tethered ligand sequences can act as biased agonists to activate different signaling pathways selectively. Furthermore, we found that selective activation of MAP kinase versus calcium signaling can occur either via a proteolytically revealed tethered ligand with a mutated receptoractivating sequence or via a synthetic soluble PAR 2 peptide agonist. Given the unusual proteolytic mechanism of activation of PAR 2 , these results represent a unique tethered ligand mechanism of biased agonism that has been documented for a variety of other GPCRs that are activated by soluble ligands (Wei et al., 2003; Galandrin et al., 2007; Kenakin, 2007; Urban et al., 2007) .
Structure-Activity Profile for the Trypsin-Revealed Tethered Ligand Sequence and MAP Kinase Activation. In our earlier work studying the roles of the tethered ligand and extracellular loop 2 for PAR 2 signaling, we used calcium signaling only as an index of receptor activation . That work pointed to differences between the interactions of the extracellular receptor domains with the proteolytically revealed tethered ligand, compared with the comparable soluble synthetic PAR-activating peptides. We were able to conclude that several distinct sites on the extracellular domains of PAR 2 can interact with TL amino acid sequences either as the intact TL or as synthetic peptides to trigger calcium signaling. We showed further that the first two amino acids of the revealed TL of PAR 2 (SL-) play a major role in triggering calcium signaling (Al-Ani et al., 2004) , but the impact of those two revealed amino acids on MAP kinase activation was not assessed. Our current work shows that when the SL sequence in the revealed TL is replaced by alanines (rPAR 2 -Ala [37] [38] ) or if the residues are simply switched in sequence (rPAR 2 -Leu 37 Ser 38 ), the ability of the revealed tethered ligand to stimulate an elevation of intracellular calcium is lost, but the activation of MAP kinase is retained. This agonist-biased signaling by the trypsin-revealed TL, with a triggering of MAP kinase but not calcium, was also observed for the synthetic PAR-activating peptide, SLAAAA-NH 2 , but not for AAIGRL-NH 2 or LSIGRL-NH 2 that were inactive for both pathways. Thus, SLAAAA-NH 2 is a biased agonist for PAR 2 and its ability to interact with the receptor seems to differ from that of the same sequence when presented to the receptor as a trypsinrevealed tethered ligand, which can activate both calcium and MAP kinase signaling.
MAP Kinase Activation and Interaction with Arrestins. Based on previous observations indicating a role for ␤-arrestin in regulating PAR 2 -stimulated MAP kinase signaling (Ge et al., 2003; Zoudilova et al., 2007; Defea, 2008) , we hypothesized that all receptor variants that can activate MAP kinase in the absence of Ca 2ϩ mobilization would do so via interaction with ␤-arrestins. It was thus surprising that the receptor mutants did not interact with ␤-arrestin-1 and -2 when triggered by trypsin (Fig. 8, C and D; Supplementary Information) . Furthermore, although the magnitude of MAP kinase activation by the wt-rPAR 2 was greater than for the TL-mutated receptors when transfected into wt-MEFs, all three receptors promoted similar levels of MAP kinase activation in the absence of ␤-arrestins (Figs. 8, B and C). These data suggest that trypsin-activated wt-rPAR 2 can activate MAP kinase by both a ␤-arrestin-dependent and ␤-arrestin-independent mechanism, whereas the mutated receptors, upon trypsin activation, can trigger MAP kinase principally via a ␤-arrestin-independent mechanism. Notwithstanding, activation of all receptor variants by the soluble PAR-activating peptide seems to trigger MAP kinase by both the-arrestin-dependent and -independent pathways, suggesting that the tethered ligand mutations do not molpharm.aspetjournals.org affect the overall signaling ability of these mutants, but rather the binding of the mutant tethered ligand domain promotes a distinct set of responses. This dual process for MAP kinase activation by PAR 2 mirrors the ability of various ␤-adrenergic receptor-targeted ligands to activate MAP kinase by distinct mechanisms (Galandrin et al., 2008) .
As reported previously, wt-PAR 2 interacts with ␤-arrestin-1 and -2, and our BRET-based analysis of this interaction revealed that PAR 2 is a class B GPCR that interacts stably with and is cointernalized with ␤-arrestin (Hamdan et al., 2005) . This stable interaction is probably due to the presence of serine and threonine clusters in the C tail of PAR 2 (residues 380-397), as has been reported for a number of other GPCRs (Oakley et al., 2001) .
Trypsin versus PAR-Activating Peptide-Stimulated Receptor Internalization and the Ability of Receptors to Interact with Arrestins. Because the interaction of PAR 2 with ␤-arrestin is critical for PAR 2 internalization (DeFea et al., 2000) and because the internalized receptor scaffold plays an important role in PAR 2 -mediated signaling and chemotaxis (Ge et al., 2003; Zoudilova et al., 2007) , we anticipated differences in internalization between the trypsinactivated receptor constructs that did and did not interact with ␤-arrestins (presence or absence of BRET signals in Fig.  9 ). Indeed, whereas trypsin triggered internalization of the wild-type PAR 2 to an extent comparable with that triggered by the PAR 2 -activating peptide (Fig. 10, ii and iii) , there was only minimal trypsin-triggered internalization of the mutated receptors PAR 2 -Leu 37 Ser 38 and PAR 2 -Ala 37-38 (Fig. 10, v and viii) . In contrast, morphometric analysis of receptor internalization (Fig. 10B ) demonstrated that the PAR 2 -activating peptide caused an equivalent internalization of all receptor constructs (Figs. 9B and 10A, iii, vi, and ix) . These observations correlated very well with the ability of SLIGRL-NH 2 , but not trypsin, to stimulate interactions between the TL-mutated receptors and ␤-arrestins (Fig. 9) .
Signaling Pathways and Activation of MAP Kinase by Trypsin-Stimulated Receptors. Given the ␤-arrestin independence of trypsin-mediated activation of MAP kinase by the mutated receptors, our focus turned to other signal pathways. Unlike other GPCR-triggered MAP kinase activation, the PAR 2 -stimulated process was not affected by either doxycycline or the EGF receptor kinase inhibitor AG1478/PD153035 (Figs.  4 to 6 ). Those data indicated that the predominant PAR 2 mechanism for activating MAP kinase in the KNRK cell background does not involve either the MMP-mediated release of an EGF receptor agonist (Daub et al., 1996) or an MMP-independent transactivation of the EGF receptor. The inhibition of either G q (GP2A) or G i (PTX treatment) had no effect on MAP kinase stimulation by the trypsin-activated mutated receptors, PAR 2 -Ala 37-38 or PAR 2 -Leu 37 Ser 38 and had only a very modest effect (approximately 30% inhibition) on trypsin-mediated activation of MAP kinase by the wt-rPAR 2 . Likewise, the Src-targeted inhibitor PP1 had no effect on trypsin-triggered activation of MAP kinase by the two mutated receptors and only a small inhibitory effect (approximately 30%) on MAP kinase activation by the wild-type receptor (Figs. 4-6) . Thus, in the KNRK cell background, the process of proteinase-mediated PAR 2 -stimulated MAP kinase activation seemed to be largely independent of pathways involving many of the common signal components (G q , G i , Src, EGFR). That said, the Rho kinase inhibitors Y27362 and H1152 had a major inhibitory effect on the ability , and rPAR 2 -Ala 37-38 were treated for 10 min at 37°C with the synthetic PAR 2 tethered ligand-related peptides, SLAAAA-NH 2 , LSIGRL-NH 2 , and AAIGRL-NH 2 or with trypsin, and the activation of MAP kinase was monitored (P-p42/44 relative to T-p42/44) by Western blot analysis as outlined by the legend to Fig. 2 . A, representative Western blot detection of the activation of MAP kinase (P-42/44, relative to T-p42/44) in wt-rPAR 2 by SLAAAA-NH 2 (third lane from left) but not by LSIGRL-NH 2 and AAIGRL-NH 2 (second and fourth lanes from left). B, representative western blots for the activation of MAP kinase (P-p42/44, relative to T-p42/44) in wt-rPAR 2 (top), rPAR 2 -Leu molpharm.aspetjournals.org of all PAR 2 constructs to stimulate MAP kinase when activated by trypsin (Figs. 4-6) . The role of Rho kinase in activation of MAP kinase by PAR 2 is in keeping with the role of this kinase for the activation of MAP kinase and other responses by PAR 1 (Vouret-Craviari et al., 1998; Seasholtz et al., 1999; Carbajal et al., 2000; McLaughlin et al., 2005) and PAR 2 (Scott et al., 2003) . Overexpression of constructs encoding G␣ 12 and G␣ 13 resulted in an increase in trypsin sensitivity of the cells to MAPK signaling, suggesting that the Rho kinase-dependent MAPK signal seen in these cells is G␣ 12/13 -dependent (Fig. 7) . Thus, in future work with intact tissue PAR 2 targets (e.g., vasculature, neurons), it will be of considerable importance to evaluate the potential role of Rho kinase and G␣ 12/13 -dependent signaling events.
We found that synthetic soluble PAR-activating peptides, like the distinct trypsin-revealed tethered ligands, are capable of agonist-biased signaling by PAR 2 . Specifically, SLIGRL-NH 2 was able to trigger both an elevation of intracellular calcium and an activation of MAP kinase, whereas SLAAAA-NH 2 triggers only MAP kinase activation (Fig. 11) without causing a calcium signal (Al-Ani et al., 2004) . In contrast with the trypsinrevealed mutated tethered ligands with the sequences, AAIGRL-(PAR 2 -Ala [37] [38] ) and LSIGRL-(PAR 2 -Leu 37 Ser 38 ), the analogous synthetic peptides with the sequences AAIGRL-NH 2 and LSIGRL-NH 2 were unable to activate either MAP kinase or calcium signaling. These results indicate that the tethered and soluble ligands most likely bind differentially and/or stabilize different conformations of the receptor leading to the activation of distinct subsets of signaling cascades. Further work will be needed to better understand the specific structural basis of this biased signaling.
In summary, we describe agonist-biased signaling by both a trypsin-revealed tethered ligand and a synthetic PAR 2 -activating peptide that can lead to the selective activation of MAP kinase versus calcium signaling by PAR 2 as well as distinctions in recruitment of ␤-arrestin and receptor endocytosis. The ability of the PAR-activating peptide, SLAAAA-NH 2 to signal selectively via MAP kinase versus calcium establishes in principle the possibility of developing signalselective PAR 2 agonists that may be of therapeutic utility.
